Merck, Glaxo Reduce Prices of HPV Vaccines in Poorest Countries

Merck, Glaxo Reduce Prices of HPV Vaccines in Poorest Countries

JB Reed/Bloomberg

Merck said one factor in determining the price is the cost involved in vaccine production and maintaining the manufacturing facilities, and that higher volumes could lower the price. The drugmaker has committed to sell 2.4 million doses of its Gardasil vaccine to GAVI from 2013 to 2017. That would generate about $11 million in revenue.